News Breaks |
|
|
| October 11, 2012 |
| 05:55 EDT |  | VRTX, VRTX, VRTX, ABT, ABT, ABT, ELMD, ELMD, ELMD, DNA, DNA, DNA, GILD, GILD, GILD, HRC, HRC, HRC, HOLX, HOLX, HOLX, NVS, NVS, NVS | Cystic Fibrosis Foundation to host a conference
26th Annual North American Cystic Fibrosis Conference (NACFC) is being held in Orlando, Florida on October 11-13. |
|
|
News For VRTX;ABT;ELMD;DNA;GILD;HRC;HOLX;NVS From The Last 14 Days Check below for free stories on VRTX;ABT;ELMD;DNA;GILD;HRC;HOLX;NVS the last two weeks. |
|
|
| May 17, 2013 |
| 16:20 EDT |  | NVS | Novartis drug Afinitor extended time without disease progression in women
 Subscribe for More Information |
|
| May 16, 2013 |
| 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| 14:02 EDT | | HOLX | Leerink's medical devices analyst holds a conference call
Medical Devices Analyst Newitter discusses Hologic's tomosynthesis (3D) technology on an Analyst/Industry conference call to be held on May 16 at 2:30 pm. |
|
| May 14, 2013 |
| 17:02 EDT |  | ELMD | Electromed reports Q3 EPS (5c), one estimate (3c)
Subscribe for More Information |
|
| May 13, 2013 |
| 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR |
|
| May 10, 2013 |
| 14:02 EDT |  | VRTX | Vertex to benefit from Welsh government decision, says Wells Fargo
Subscribe for More Information |
| |
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
| May 9, 2013 |
| 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information |
|
| May 8, 2013 |
| 09:32 EDT |  | HRC | Hill-Rom upgraded to Neutral from Sell at CL King
Subscribe for More Information |
|
| May 7, 2013 |
| 12:29 EDT | | HOLX | High option volume stocks: GNK CVR ACM BA HOLX
Subscribe for More Information |
|
| 10:00 EDT |  | HOLX | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Aeropostale (ARO) downgraded to Sell from Hold at Brean Capital... AIG (AIG) downgraded to Neutral from Buy at Goldman... Alpha Natural (ANR) downgraded to Sell from Neutral at Goldman... American Eagle (AEO) downgraded to Market Perform from Outperform at Wells Fargo... Coach (COH) downgraded to Market Perform from Outperform at Wells Fargo... Iconix Brand (ICON) downgraded to Hold from Buy at Brean Capital... International Rectifier (IRF) downgraded to Market Perform at JMP Securities... Mettler-Toledo (MTD) downgraded to Hold from Buy at Jefferies... TJX (TJX) downgraded to Market Perform from Outperform at Wells Fargo... Tiffany (TIF) downgraded to Market Perform from Outperform at Wells Fargo... North American Palladium (PAL) downgraded to Market Perform at Raymond James... Ducommun (DCO) downgraded to Neutral from Buy at B. Riley... International Rectifier (IRF) downgraded at JMP Securities... Hologic (HOLX) downgraded to Buy from Strong Buy at ISI Group... Ruckus Wireless (RKUS) downgraded to Neutral from Buy at Lazard Capital. |
|
| 09:00 EDT |  | HOLX | Hologic falls 4.2%
Hologic is down 4.2%, or 86c, to $19.80 |
|
| 08:58 EDT | | HRC | Hill-Rom sees FY13 EPS $2.03-$2.09, consensus $2.06
Subscribe for More Information |
|
| 07:24 EDT | | HOLX | Hologic downgraded to Buy from Strong Buy at ISI Group
ISI Group downgraded Hologic following the Q2 report and lowered guidance. |
|
| 06:57 EDT | | HOLX | Hologic downgraded to Outperform from Strong Buy at Raymond James
|
|
| May 6, 2013 |
| 16:23 EDT | | NVS | Array to start first company-led Phase 3 trial with MEK162
Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. |
| |
|
|
|
|
